Eye Diseases: Diabetic macular oedema Eye Diseases Diabetic macular oedema
Conditions
Interventions
Triamcinolone vs no triamcinolone
Sponsors
Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Diabetic Mellitus, Type 1 or 2 Eligible 2. Patients with cataract sufficient in an eye to cause visual symptoms 3. Patients who have persistent CSME despite previous later treatment 4. Patients who have moderate or severs NPDR and treated PDR as defined by a clinical modification of the Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy scale 5. OCT measurements of <300 micron at central subfold of fats macula map
Exclusion criteria
Exclusion criteria: 1. Patients with no CSME 2. High risk proliferative retinopathy as defined by the DRS 17 3. Diabetes associated with specific genetic conditions, induced by drugs, chemicals or endocrinopathies 4. Coexistent ocular disease 5. Coexistent disease likely to affect retinopathy progression, for example severe carotid occlusive disease 6. Patients with coexistent disease likely to respond poorly to side effects of intravitreal triamcinalone, including glaucoma, OHT, steroid responders 7. Prior intraocular surgery to either eye 8. Complicated cataract surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular oedema at 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Visual acuity at 1 year 2. Macular thickness/volume 3. Retinopathy progression 4. Capsular opacification 5. Macular ischaemia | — |
Countries
United Kingdom
Outcome results
None listed